The company is revolutionizing regenerative healthcare through innovation, clinical alignment and GMP excellence across Southeast Asia.
SAN ANTONIO, December 15, 2025 /PRNewswire/ — Frost and Sullivan is pleased to announce that MEDEZE Group Public Company Limited (MEDEZE) has been awarded the 2025 Southeast Asia Company of the Year in Stem Cell Banking and Regenerative Medicine for its outstanding achievements in innovation, regulatory leadership and clinical alignment. This recognition highlights MEDEZE’s leadership in advancing the next generation of personalized healthcare solutions while maintaining the highest global standards in safety, technology and compliance.
Frost & Sullivan evaluates companies using a rigorous benchmarking process focusing on two primary dimensions: effectiveness and strategy execution. MEDEZE has excelled in both areas, demonstrating its ability to align strategic initiatives with market demand while executing them with precision and scale. “MEDEZE is redefining stem cell banking in Southeast Asia through full-spectrum, clinically aligned solutions, leveraging innovation, regulatory leadership and GMP quality infrastructure to lead the transition from cell preservation to personalized medical application,” said Unmesh Lal, Vice President, Healthcare and Life Sciences at Frost & Sullivan.
Driven by a long-term strategy focused on innovation, clinical readiness and international expansion, MEDEZE has built one of the most comprehensive and technologically advanced cell banking ecosystems in the region. Its vertically integrated model, covering biological material collection, diagnosis, cell processing, storage, expansion and clinical application, ensures consistent quality, regulatory compliance and scalability across Southeast Asia.
Innovation is at the heart of MEDEZE’s success. Proprietary technologies, such as the AutoXpress system for fully automated cord blood processing and the Chibuya robotic stem cell culture system (the world’s first complete cleanroom automation), enable therapeutic-grade manufacturing at scale. The Company’s AI-based hair follicle restoration platform and Japan’s proprietary NK cell diagnostic technologies demonstrate its ability to extend cellular applications to clinical and aesthetic care.
MEDEZE’s commitment to international accreditation and operational excellence strengthens its leadership in regenerative medicine. It is the only Thai stem cell bank accredited by the American Association for the Advancement of Blood and Biotherapeutics (AABB) and holds ISO 9001 and ISO 22716 certifications. These accreditations reinforce the company’s compliance with the highest safety and quality standards in therapeutic and wellness applications.
Supported by a network of more than 260 hospital partners, including leading institutions such as Samitivej Hospital Group and Bangkok Hospital, MEDEZE plays a central role in the ADMP Sandbox clinical program in Thailand. With ongoing trials in osteoarthritis, degenerative disc disease, skin rejuvenation, colorectal cancer and immune system enhancement, MEDEZE is on track to become one of the first private companies in Southeast Asia to commercialize licensed cell therapies by 2026.
Frost & Sullivan congratulates MEDEZE for setting a new benchmark for competitive strategy, innovation and market responsiveness. Its integrated operating model, financial strength and commitment to sustainable growth illustrate its leadership in biotechnology and position it at the forefront of Southeast Asia’s transition to licensed regenerative therapies.
Each year, Frost & Sullivan awards the Company of the Year title to an organization that demonstrates exceptional strategy development and execution, resulting in measurable improvements in market share, customer satisfaction and competitive positioning. This recognition recognizes forward-thinking companies that are redefining their industries through innovation and growth excellence.
Frost & Sullivan Best Practices Recognition
Frost & Sullivan Best Practices recognitions recognize companies in regional and global markets that demonstrate exceptional achievement and consistent excellence in areas such as leadership, technology innovation, customer experience and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts evaluate performance through comprehensive interviews, in-depth analysis and extensive secondary research. The goal is to identify the best organizations that are driving transformative growth and setting new industry standards.
Contact us: start the discussion.
Contact:
Tarini Singh
E : Tarini.Singh@frost.com
SOURCE Gros & Sullivan
